Clinical Safety · GLP-1 Therapy
Most people discover this from a wearable rather than from a clinic visit. Resting heart rate had been sitting at 58 for two years, and six weeks into tirzepatide the weekly summary reports 63, with nothing else feeling different. The number has simply moved, and it has moved in the direction nobody wants a cardiac number to move.
This is one of the most reliably reproduced findings in incretin research, since every large trial of tirzepatide, semaglutide, liraglutide, dulaglutide, and exenatide has recorded the same small upward shift in resting heart rate, and regulators have taken it seriously enough to require dedicated monitoring studies. What tends to get lost in the alarm is the size of the change, the direction of everything measured alongside it, and the fact that the trials which followed people long enough to count heart attacks and strokes reported fewer of them rather than more. Understanding why those two observations sit together is most of the work here.
Published evidence indicates that tirzepatide raises resting heart rate by roughly 2 to 4 beats per minute on average, a finding measured consistently across the SURPASS trials in type 2 diabetes and the SURMOUNT trials in weight management. The effect appears dose related, meaning that higher maintenance doses have tended to produce slightly larger average increases than starting doses.
The most detailed picture comes from an ambulatory blood pressure monitoring substudy of SURMOUNT-1, which regulators required specifically to rule out excessive heart rate elevation. Rather than relying on clinic readings taken at a single moment, the substudy fitted 600 participants with 24 hour monitors and followed them for 36 weeks, and average 24 hour heart rate rose by 2.1 to 5.4 beats per minute depending on the dose arm. That design matters because it captured sleep, work, and everything in between rather than one measurement taken shortly after someone had walked in from a parking lot.
Figure 1
24 Hour Average Heart Rate Increase by Dose Arm, SURMOUNT-1 Monitoring Substudy
Source: Ambulatory blood pressure monitoring substudy of SURMOUNT-1, in which 600 participants wore 24 hour monitors over 36 weeks. Reported 24 hour average heart rate increases spanned 2.1 to 5.4 beats per minute across the 5 mg, 10 mg, and 15 mg arms, with the intermediate arm falling between the two values shown. Individual results vary.
Averages of this kind conceal how differently individual people respond, and the distribution reported in the trial population was notably wide. A substantial minority saw no measurable change at all, the majority landed somewhere between 1 and 6 beats per minute, and a similar sized minority to the non responders rose by 7 beats per minute or more. Two people taking the same 10 mg dose can therefore have genuinely different pulse trajectories, and neither of them is doing anything wrong.
Figure 2
Distribution of Individual Heart Rate Responses Reported in SURMOUNT-1
Source: Reported distribution of individual heart rate responses among SURMOUNT-1 participants. Percentages are approximate and are shown to illustrate the spread of responses rather than as precise figures for any single dose arm. The size of an individual response cannot currently be predicted before treatment begins. Individual results vary.
Tirzepatide raises heart rate mainly because GLP-1 receptors are expressed on the sinoatrial node, the cluster of cells in the right atrium that establishes the heart's intrinsic rhythm. Activating those receptors speeds the firing rate of the node directly, without requiring any signal from the brain or the adrenal glands.
This was established in experimental preparations where the heart had been isolated from its nerve supply entirely, and GLP-1 still increased the rate, which rules out the intuitive explanation that these medications work by making the body feel stressed. Work published in Cardiovascular Research has characterized the finding as a direct chronotropic action on the sinus node mediated through the GLP-1 receptor itself.
A second contribution comes from the autonomic side. Holter monitoring studies using heart rate variability analysis have found that incretin medications shift the autonomic balance by reducing parasympathetic tone, and since the vagus nerve normally acts as a continuous brake on heart rate, easing that brake raises the resting pulse even when sympathetic activity is unchanged. The practical result is the same few beats per minute arriving through a different route.
Tirzepatide also activates the GIP receptor, which is what distinguishes it from single agonist medications in this class. The specific contribution of GIP receptor activation to heart rate remains less well characterized than the GLP-1 pathway, and the magnitude of the effect observed with tirzepatide sits within the range reported for GLP-1 receptor agonists rather than above it.
The increase typically appears within the first several weeks of starting tirzepatide or after a dose escalation, and it generally plateaus rather than continuing to climb indefinitely. Most people reach a new stable baseline during the first two to three months of titration.
This pattern follows directly from the pharmacology, since tirzepatide has a half life of around five days and reaches steady state concentrations after roughly four to five weeks at a given dose, so each step up the titration ladder tends to produce its own small adjustment period before levelling off. People who track heart rate continuously often describe seeing a visible step at each escalation rather than a smooth ramp upward.
Figure 3
Typical Shape of the Heart Rate Change Across Titration (Schematic)
Note: This figure is a schematic representation of the shape and timing described in the trial literature rather than measured values from any single study, and the plotted points are illustrative. Each dose escalation can produce its own small step before the curve levels off. Individual results vary considerably in both magnitude and timing.
Whether the increase reverses over longer periods is less settled in the literature. Some longitudinal data suggest partial attenuation as substantial weight loss accumulates, which would make physiological sense given that weight loss on its own tends to lower resting heart rate, so the two effects run in opposite directions and where an individual lands depends on which one dominates. Discontinuing tirzepatide reverses the contribution of the medication as the drug clears, typically over a period of several weeks.
The evidence available so far does not indicate that the heart rate increase seen with incretin medications translates into worse cardiovascular outcomes, and the trials designed specifically to count cardiovascular events have reported the opposite pattern.
The clearest illustration comes from the SELECT trial of semaglutide in people with overweight or obesity and established cardiovascular disease, which is a different molecule from tirzepatide although it belongs to the same class. Participants showed the familiar heart rate increase of roughly 3 beats per minute, and the primary composite cardiovascular endpoint occurred in 6.5% of the treatment group compared with 8.0% of the placebo group, a relative reduction of about 20%. If a few beats per minute carried meaningful harm at this scale, a trial powered to detect cardiovascular events across more than 17,000 high risk participants was well positioned to reveal it.
Figure 4
Major Adverse Cardiovascular Events in the SELECT Trial of Semaglutide
Source: SELECT cardiovascular outcomes trial of semaglutide in adults with overweight or obesity and established cardiovascular disease. SELECT studied semaglutide rather than tirzepatide, and no equivalent completed cardiovascular outcomes trial for tirzepatide in this population is available, so the finding describes the medication class rather than tirzepatide specifically. Individual results vary.
Part of the explanation is that the pulse change does not travel alone, since in the SURMOUNT-1 monitoring substudy the same participants whose heart rate rose by 2.1 to 5.4 beats per minute saw 24 hour systolic blood pressure fall by 7.4 to 10.6 mmHg. Alongside that come the changes in weight, glycemic control, lipids, and inflammatory markers reported across the trial programs, so the composite picture is one of reduced cardiovascular load rather than increased strain.
This reasoning applies to the modest and gradual increase that characterizes the expected response, and it is not a reason to disregard a pulse that climbs sharply, sits persistently above 100 beats per minute at rest, or arrives together with symptoms. Those patterns fall outside what the trial data describe and deserve individual clinical evaluation.
Several common circumstances during tirzepatide treatment raise heart rate independently of any direct cardiac effect of the medication, and they are worth ruling out before a reading is attributed to the drug itself.
Dehydration is the most frequent contributor. Reduced appetite often means reduced fluid intake, and nausea, vomiting, or diarrhea during titration compound the deficit, so lower circulating volume raises heart rate as a compensatory response. This version typically arrives with lightheadedness on standing and darker urine, and the reading tends to improve within hours of proper rehydration.
Nutritional gaps matter as well. Rapid weight loss can outpace nutritional intake, and low iron or low vitamin B12 producing anemia will raise resting heart rate, which is one of the reasons periodic lab monitoring is worth maintaining during active weight loss rather than only at the start of treatment. Thyroid function belongs in the same category, since an overactive thyroid raises resting pulse and can be uncovered during a period of metabolic change.
Anxiety, poor sleep, alcohol, caffeine, decongestants, and stimulant medications all contribute in the usual way, and none of them stop contributing simply because someone has started tirzepatide. There is also a measurement question worth acknowledging, because people who begin a weight management medication frequently begin wearing a fitness tracker at the same time, and a resting heart rate that appears elevated may be the first accurate measurement someone has ever had rather than a change from a known baseline.
Figure 5
Approximate Magnitude of Common Influences on Resting Heart Rate
Note: Values other than the tirzepatide figure are approximate typical magnitudes drawn from general physiology literature and are shown for orientation rather than as precise measurements, since each varies substantially by individual, dose, and circumstance. The purpose of the comparison is to place the medication effect in context, not to suggest that any of these influences can be substituted for clinical assessment. Individual results vary.
A clinician should be contacted if resting heart rate stays above 100 beats per minute, if the pulse feels irregular or appears to skip, or if any heart rate change arrives together with chest pain, shortness of breath, dizziness, fainting, or swelling in the legs. These patterns fall outside the expected response regardless of how small the numeric change looks on a wearable.
| Pattern | What it usually looks like | Suggested response |
|---|---|---|
| Expected adjustment | A gradual rise of 2 to 6 beats per minute over the weeks after starting or escalating, with no symptoms of any kind | Mention at a routine review |
| Larger than average | A sustained rise of 7 beats per minute or more, still without symptoms, that persists after a dose has been held steady | Raise with the prescriber |
| Likely secondary cause | An abrupt rise during a period of poor intake, vomiting, diarrhea, or illness, often with lightheadedness on standing | Address hydration and contact the clinic |
| Outside the expected pattern | Resting heart rate persistently above 100 beats per minute, or a rhythm that feels irregular rather than simply fast | Clinical assessment |
| Requires urgent attention | Any pulse change accompanied by chest pain, breathlessness at rest, fainting, or new swelling in the legs | Seek prompt medical care |
This table is a general orientation rather than a clinical protocol, and it does not replace the judgement of the clinician managing an individual course of treatment. Anyone uncertain about a symptom should seek advice rather than attempt to categorise it.
A gradual drift of a few beats per minute with no symptoms, arriving in the weeks after starting or escalating a dose, matches what the trials describe and is worth mentioning at a routine check in rather than treating as urgent. Bringing a record helps considerably more than a single reading does, and most wearables will export several weeks of resting heart rate trend data for that purpose.
Some clinical situations call for closer attention from the outset, and people with existing arrhythmias, heart failure, coronary artery disease, or who take rate controlling medications such as beta blockers should have heart rate monitoring built into the treatment plan from the beginning. That conversation belongs before the first dose rather than after the first alarming notification from a watch.
Tirzepatide moves resting heart rate upward by a few beats per minute reliably enough that regulators required a dedicated study to quantify it, and the answer that study produced was a 24 hour average increase of 2.1 to 5.4 beats per minute alongside a systolic blood pressure reduction two to three times larger in the opposite direction. The mechanism described in the research involves direct action on the heart's own pacemaker together with a lighter parasympathetic brake, rather than the adrenaline driven response that the phrase elevated heart rate tends to suggest.
Trials in this medication class that followed participants long enough to count cardiovascular events reported fewer of them, and the everyday explanations for an elevated pulse, dehydration above all, remain considerably more common during titration than anything cardiac. None of which makes a persistent resting rate above 100 beats per minute, an irregular rhythm, or accompanying chest symptoms into something to wait out, since those patterns sit outside the expected response, and distinguishing between the two is precisely what a clinician is for.
A 3 minute intake is all it takes. A physician reviews your information and identifies the protocol matched to your specific symptom profile.
See Our Protocols